


Current Trial Design



*Patients for whom GO is unsuitable/ unavailable can be randomised to DA alone versus CPX-351. Patients for whom CPX is unsuitable/unavailable will be allocated DA alone in course 1.

*Randomisation to AC220 vs chemo alone (1:1) following course 1 for FLT3 mutated patients who have received DA (+/- GO2) in course 1 only. Patients allocated AC220 will be allocated to maintenance or not at this point.